EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemia

Chiharu Ishikawa, Laura Barreyro, Avery M Sampson, Kathleen M Hueneman, Kwangmin Choi, Sophia Y Philbrook, Issac Choi, Lyndsey C Bolanos, Mark Wunderlich, Andrew G Volk, Stephanie S Watowich, Kenneth D Greis und 1 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci184665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Chiharu Ishikawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Ubiquitin-Conjugating Enzymes, Leukemia, Myeloid, Acute, Proteostasis, Proteasome Endopeptidase Complex. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Altered protein homeostasis through proteasomal degradation of ubiquitinated proteins is a hallmark of many cancers. Ubiquitination, coordinated by E1, E2, and E3 enzymes, involves up to 40 E2-conjugating enzymes in humans to specify substrates and ubiquitin linkages. In a screen for E2 dependencies in acute myeloid leukemia (AML), ubiquitin conjugating enzyme E2 N (UBE2N) emerged as the top candidate. To investigate UBE2N’s role in AML, we characterized an enzymatically defective mouse model of UBE2N, revealing UBE2N’s requirement in AML without an impact on normal hematopoiesis. Unlike other E2s, which mediate lysine-48 (K48) polyubiquitination and degradation of proteins, UBE2N primarily synthesizes K63-linked chains, stabilizing or altering protein function. Proteomic analyses and a whole-genome CRISPR-activation screen in pharmacologically and genetically UBE2N-inhibited AML cells unveiled a network of UBE2N-regulated proteins, many of which are implicated in cancer. UBE2N inhibition reduced their protein levels, leading to increased K48-linked ubiquitination and degradation through the immunoproteasome and revealing UBE2N activity is enriched in immunoproteasome-positive AML. Furthermore, an interactome screen identified tripartite motif–containing protein 21 (TRIM21) as the E3 ligase partnering with activated UBE2N in AML to modulate UBE2N-dependent proteostasis. In conclusion, UBE2N maintains proteostasis in AML by stabilizing target proteins through K63-linked ubiquitination and prevention of K48 ubiquitin–mediated degradation by the immunoproteasome. Thus, inhibition of UBE2N catalytic function suppresses leukemic cells through selective degradation of critical proteins in immunoproteasome-positive AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Conjugating EnzymesLeukemia, Myeloid, AcuteProteostasisProteasome Endopeptidase ComplexNeoplasm ProteinsAnimalsMiceHumansUbiquitinationMice, Knockout

Stichwörter der Autor:innen

HematologyLeukemiasOncologyUbiquitin-proteosome system

Substanzen

Ubiquitin-Conjugating EnzymesProteasome Endopeptidase ComplexUbe2n protein, mouseNeoplasm Proteins

Autor:innen und Institutionen

  • Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Cancer Biology, University of Cincinnati, Cincinnati, Ohio, USA.
  • Department of Immunology, MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.
  • University of Cincinnati Cancer Center, Cincinnati, USA.

Förderung

  • NIEHS NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NIH
  • NIH Office of the Director

Zitieren

APA

Ishikawa, C., Barreyro, L., Sampson, A. M., Hueneman, K. M., Choi, K., Philbrook, S. Y., Choi, I., Bolanos, L. C., Wunderlich, M., Volk, A. G., Watowich, S. S., Greis, K. D., & Starczynowski, D. T. (2025). Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemia. Journal of Clinical Investigation. https://doi.org/10.1172/jci184665

Vancouver

Ishikawa C, Barreyro L, Sampson AM, Hueneman KM, Choi K, Philbrook SY, et al. Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemia. Journal of Clinical Investigation. 2025. doi:10.1172/jci184665

BibTeX
@article{Ishikawa2025,
  author = {Ishikawa, Chiharu and Barreyro, Laura and Sampson, Avery M and Hueneman, Kathleen M and Choi, Kwangmin and Philbrook, Sophia Y and Choi, Issac and Bolanos, Lyndsey C and Wunderlich, Mark and Volk, Andrew G and Watowich, Stephanie S and Greis, Kenneth D and Starczynowski, Daniel T},
  title = {Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemia},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci184665}
}
Kostenlos starten →